Comparative Pharmacology
Head-to-head clinical analysis: HYDELTRASOL versus HYDROCORTONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDELTRASOL versus HYDROCORTONE.
HYDELTRASOL vs HYDROCORTONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid with anti-inflammatory and immunosuppressive properties; suppresses multiple inflammatory cytokines and induces lipocortin synthesis.
Hydrocortisone is a corticosteroid that binds to the glucocorticoid receptor, leading to anti-inflammatory and immunosuppressive effects by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppressing cytokine production.
Intravenous: Initial dose 100-250 mg, then repeat every 10-30 minutes as needed. Intramuscular: 100-250 mg every 10-30 minutes. Intra-articular: 10-40 mg per joint every 1-2 weeks.
100-500 mg intravenously every 2-6 hours for initial management of adrenal insufficiency; oral maintenance: 20-30 mg daily in divided doses (e.g., 10 mg morning, 5 mg afternoon).
None Documented
None Documented
Terminal half-life ~2-3 hours; clinically, adrenal suppression may persist >24h.
Terminal elimination half-life: 1.5–2.5 hours (plasma), but biological half-life (duration of HPA axis suppression) is 8–12 hours.
Renally eliminated: ~80% as metabolites, <10% unchanged. Biliary/fecal: minor.
Renal (primarily as inactive metabolites; <5% unchanged) and biliary/fecal (minor).
Category C
Category C
Corticosteroid
Corticosteroid